TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02708147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotheraphy + Conventional treatment
Description: The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
Study: NCT00852241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perlane
Description: One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
Study: NCT03369236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danicopan
Description: Danicopan was administered as an oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danicopan
Description: Danicopan was administered as an oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo was administered as an oral tablet.
Study: NCT05982002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy-restricted diet
Description: energy intake was 500K calorie below daily requirements on average three meals at the same time of the day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet
Description: energy intake was 500K calorie below daily requirements on average three meals at the same time of the day
Study: NCT02698111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: donafenib 200mg，bid
Study: NCT01820455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine, Mupirocin
Description: Chlorhexidine baths and intranasal mupirocin ointment once daily for five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soap baths, Lubricating Jelly
Description: Soap and water baths with lubricating jelly to the nares, once daily for 5 days
Study: NCT04160494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every three weeks)
Description: programmed cell death ligand 1 (PD-L1) blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every three weeks)
Description: programmed cell death ligand 1 (PD-L1) blocking antibody
Study: NCT05017961

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft
Description: An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.

Intervention type: DEVICE
Group type: OTHER
Intervention: Allograft only
Description: The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.

Intervention type: DEVICE
Group type: OTHER
Intervention: Allograft combined with BMAC
Description: A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
Study: NCT01119781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017(peginterferon beta-1a)
Description: peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
Study: NCT03806608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crestal
Description: Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcrestal
Description: Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
Study: NCT02619643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (Magstim)
Study: NCT02312258

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ixazomib placebo-matching capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study: NCT03147222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fracture Care at Home
Description: This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
Study: NCT03730727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal
Description: Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
Study: NCT01649531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 Implants
Study: NCT02619643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)
Study: NCT03672253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T Re-treatment
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
Study: NCT02049970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
Study: NCT04160494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
Description: dual-specific mAB
Study: NCT04426227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze training
Description: A training module in gaze training for peripheral nerve blockade
Study: NCT02049970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 30 ml 0.25 % bupivacaine is applied around brachial plexus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 30 ml 0.25 % bupivacaine is applied around brachial plexus
Study: NCT02587091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portable obstetric ultrasound
Description: This intervention was advertised at the cluster level
Study: NCT04663191

Intervention type: PROCEDURE
Intervention: anatomical resection
Description: Anatomical resection with systematic lymph-node dissection

Intervention type: PROCEDURE
Intervention: anatomical resection
Description: Anatomical resection with systematic lymph-node dissection

Intervention type: PROCEDURE
Intervention: anatomical resection
Description: Anatomical resection with systematic lymph-node dissection
Study: NCT01290159

Intervention type: OTHER
Intervention: heat tolerance test (HTT)
Description: An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.

Intervention type: OTHER
Intervention: heat tolerance test (HTT)
Description: An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.

Intervention type: OTHER
Intervention: heat tolerance test (HTT)
Description: An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
Study: NCT03198676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001 6.4 mg
Description: 6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001 6.4 mg
Description: 6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001 3.2 mg
Description: 3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
Study: NCT02057887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10660A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10660A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10660A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 mcg Pegasys SC once weekly
Study: NCT04087915

Intervention type: DRUG
Intervention: Evolocumab
Description: Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
Study: NCT04426227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discovery learning
Description: A phase of discovery learning guided by novice operators themselves
Study: NCT04238650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02 (Bevacizumab Biosimilar)
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU approved Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
Study: NCT01221610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DRB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PTA (POBA)
Study: NCT04607057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition Solutions
Description: * Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN
Study: NCT01688557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)
Description: NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy (Olympus CF-H180DL)
Description: Conventional colonoscopy performed without innovative techniques used in experimental arm.
Study: NCT01050465

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health information prescription
Description: Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
Study: NCT02744651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA
Description: Please note the text in section Arm description
Study: NCT00999817

Intervention type: DRUG
Group type: OTHER
Intervention: reference [dextromethorphan]
Description: single 30 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test [PF-00299804 + dextromethorphan]
Description: single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
Study: NCT00980447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMN-0501
Description: 2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMN-0501
Description: 2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMN-0501
Description: 2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
Study: NCT01822626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational counseling
Description: A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
Study: NCT02023294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Convetional laparoscopic Sleeve Gastrectomy
Description: Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILS Sleeve gastrectomy
Description: Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
Study: NCT04022876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 of every 21-day cycle.
Study: NCT02744651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Endodrill biopsy
Description: Please note the text in section Arm description
Study: NCT00654459

Intervention type: DIETARY_SUPPLEMENT
Intervention: Mixture of Berberine, Policosanol, Red Yeast, Placebo
Description: A tablet one a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Intervention: Mixture of Berberine, Policosanol, Red Yeast, Placebo
Description: A tablet one a day for 6 weeks
Study: NCT00118430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants
Description: Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
Study: NCT00171847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT03730727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
Study: NCT02541292

Intervention type: OTHER
Intervention: No intervention, observational
Study: NCT00171847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT01332747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safoof e muhazzil
Description: drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily